G
Gordon H. Guyatt
Researcher at McMaster University
Publications - 1749
Citations - 262329
Gordon H. Guyatt is an academic researcher from McMaster University. The author has contributed to research in topics: Randomized controlled trial & Medicine. The author has an hindex of 231, co-authored 1620 publications receiving 228631 citations. Previous affiliations of Gordon H. Guyatt include Memorial Sloan Kettering Cancer Center & Cayetano Heredia University.
Papers
More filters
Journal ArticleDOI
How Strong Is the Evidence
TL;DR: How Strong Is the Evidence?
Journal Article
Users' guide to the surgical literature: how to use a systematic literature review and meta-analysis.
TL;DR: An evidence-based approach to surgery incorporates patients’ circumstances or predicaments, identifies knowledge gaps and frames questions to fill those gaps, conducts efficient literature searches, critically appraises the research evidence and applies that evidence to patient care.
Journal ArticleDOI
Symbols were superior to numbers for presenting strength of recommendations to health care consumers: a randomized trial.
Elie A. Akl,Nancy Maroun,Gordon H. Guyatt,Andrew D Oxman,Pablo Alonso-Coello,Gunn Elisabeth Vist,Philip J. Devereaux,Victor M. Montori,Holger J. Schünemann +8 more
TL;DR: Objective understanding was high for both symbols and letters for the presentation of the QOE, but letters conveyed the SOR better than symbols, and symbols were superior to numbers for the presented SOR.
Journal ArticleDOI
Optimising first- and second-line treatment strategies for untreated major depressive disorder — the SUN☺D study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial
Tadashi Kato,Toshi A. Furukawa,Akio Mantani,Kenichi Kurata,Hajime Kubouchi,Susumu Hirota,Hirotoshi Sato,Kazuyuki Sugishita,Bun Chino,Kahori Itoh,Yoshio Ikeda,Yoshihiro Shinagawa,Masaki Kondo,Yasumasa Okamoto,Hirokazu Fujita,Motomu Suga,Shingo Yasumoto,Naohisa Tsujino,Takeshi Inoue,Noboru Fujise,Tatsuo Akechi,Mitsuhiko Yamada,Shinji Shimodera,Norio Watanabe,Masatoshi Inagaki,Kazuhira Miki,Yusuke Ogawa,Nozomi Takeshima,Yu Hayasaka,Aran Tajika,Kiyomi Shinohara,Naohiro Yonemoto,Shiro Tanaka,Qi Zhou,Gordon H. Guyatt +34 more
TL;DR: In patients with new onset depression, this multi-centre, open-label, assessor-blinded, pragmatic trial found no advantage of titrating sertraline to 100 mg vs 50 mg, and patients unremitted by week 3 gained a small benefit in reduction of depressive symptoms at week 9 by switching sertRALine to mirtazapine or by adding mirtzapine.
Journal ArticleDOI
A number of factors explain why WHO guideline developers make strong recommendations inconsistent with GRADE guidance
Paul E. Alexander,Michael R. Gionfriddo,Shelly-Anne Li,Lisa Bero,Rebecca J. Stoltzfus,Ignacio Neumann,Ignacio Neumann,Juan P. Brito,Benjamin Djulbegovic,Victor M. Montori,Susan L Norris,Holger J. Schünemann,Lehana Thabane,Gordon H. Guyatt +13 more
TL;DR: In this paper, the authors interviewed panel members involved in guidelines approved by the World Health Organization (2007-2012) that included discordant recommendations and found that many such recommendations are inconsistent with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidance.